By Sabela Ojea
Shares of Ardelyx rose after the company disclosed that its chairman, David Mott, has increased its stake in the company.
The stock was up 7.1%, to $5.41, in Wednesday post-market trading. Through the close, shares have dropped 41% over the past 12 months.
Mott, who has served as the biotechnology's chairman of the board since 2009, acquired 199,000 shares in the company, according to a Securities and Exchange Commission filing.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
January 22, 2025 18:25 ET (23:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。